Home Cart Sign in  
Chemical Structure| 2095625-97-9 Chemical Structure| 2095625-97-9

Structure of Milademetan tosylate hydrate
CAS No.: 2095625-97-9

Chemical Structure| 2095625-97-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

DS-3032b is an orally available MDM2 (murine double minute 2) antagonist with potential antineoplastic activity.

Synonyms: DS-3032b; DS-3032 tosylate hydrate

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Milademetan tosylate hydrate

CAS No. :2095625-97-9
Formula : C37H44Cl2FN5O8S
M.W : 808.74
SMILES Code : O=C(N)[C@H]1OC[C@H](NC([C@@H]2NC3(CCC(C)(C)CC3)[C@](C4=O)(C5=CC=C(Cl)C=C5N4)[C@H]2C6=CC=NC(Cl)=C6F)=O)CC1.CC7=CC=C(S(O)(=O)=O)C=C7.O
Synonyms :
DS-3032b; DS-3032 tosylate hydrate
MDL No. :N/A

Safety of Milademetan tosylate hydrate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Milademetan tosylate hydrate

GPCR

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03552029 Acute Myeloid Leukemia Phase 1 Recruiting October 15, 2021 United States, Texas ... More >> MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Principal Investigator    713-794-4392    NDaver@mdanderson.org Less <<
NCT03671564 Acute Myeloid Leukemia Phase 1 Recruiting June 30, 2019 Japan ... More >> Japanese Red Cross Narita Hospital Recruiting Chiba, Japan, 286-0041 Contact: See Central Contact          Gifu Municipal Hospital Recruiting Gifu, Japan, 500-8513 Contact: See Central Contact          Chugoku Central Hospital Recruiting Hiroshima, Japan, 720-0001 Contact: See Central Contact          Tenri Hospital Recruiting Nara, Japan, 632-8552 Contact: See Central Contact          NTT Medical Center Tokyo Recruiting Tokyo, Japan, 141-8625 Contact: See Central Contact          National Hospital Organization Disaster Medical Center Recruiting Tokyo, Japan, 190-0014 Contact: See Central Contact Less <<
NCT02319369 Acute Myelogenous Leukemia ... More >> Myelodysplastic Syndrome Less << Phase 1 Recruiting July 2021 United States, California ... More >> City of Hope National Medical Center Completed Duarte, California, United States, 91010 University of California San Francisco Medical Center Active, not recruiting San Francisco, California, United States, 94143 United States, Texas M D Anderson Recruiting Houston, Texas, United States, 77031 Less <<
NCT03634228 Acute Myeloid Leukemia Arising... More >> From Previous Myelodysplastic Syndrome Recurrent Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia TP53 Gene Mutation Negative Less << Phase 1 Phase 2 Not yet recruiting May 1, 2020 United States, Texas ... More >> M D Anderson Cancer Center Not yet recruiting Houston, Texas, United States, 77030 Contact: Kiran Naqvi    713-745-6877    knaqvi@mdanderson.org    Principal Investigator: Kiran Naqvi Less <<
NCT02579824 Myeloma Phase 1 Recruiting August 2021 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Less <<
NCT01877382 Advanced Solid Tumor ... More >> Lymphoma Less << Phase 1 Recruiting March 2020 United States, Michigan ... More >> Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 United States, New York Columbia University College of Physicians and Surgeons Recruiting New York, New York, United States, 10032 Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Mrinal Gounder    646-888-4167    gounderm@mskcc.org    United States, Tennessee Tennessee Oncology Completed Nashville, Tennessee, United States, 37203 United States, Texas UT MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.24mL

0.25mL

0.12mL

6.18mL

1.24mL

0.62mL

12.36mL

2.47mL

1.24mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories